Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SPECTRUM PHARMACEUTICALS, INC. (SPPI)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Spectrum Pharmaceuticals, Inc. : Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2013 | 02:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or "The Company") following the filing of a class-action lawsuit on behalf of investors. The firm encourages those who have suffered losses to contact Hagens Berman Partner Reed Kathrein, who is leading the Firm's investigation, by emailing [email protected].

A class-action lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Those who suffered significant losses and wish to move to be a lead plaintiff may also contact the firm by calling (510) 725-3000.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

"We are concerned that Spectrum knew that generic competition would substantially impact the company's revenues and failed to disclose these concerns to investors," said Mr. Kathrein. "We believe the company's alleged failure to come clean with investors about these issues may have artificially inflated the stock price, resulting in very significant investor losses."

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
05/17SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Bank of America Me..
AQ
05/16SPECTRUM PHARMACEUTICALS : CORRECTING and REPLACING Spectrum Pharmaceuticals Ann..
BU
05/15SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Bank of America Me..
AQ
05/10SPECTRUM PHARMACEUTICALS : Announces Corporate Governance Enhancements and Board..
AQ
05/10SPECTRUM PHARMACEUTICALS : Announces Exclusive Licensing Agreement on Certain Me..
AQ
05/10SPECTRUM PHARMACEUTICALS : Reports First Quarter 2018 Financial Results and Pipe..
AQ
05/09SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Bank of America Me..
BU
05/07SPECTRUM PHARMACEUTICALS, INC. : Blog Exposure - Spectrum Pharma Inked Licensing..
AC
05/07SPECTRUM PHARMACEUTICALS : Enters into a Next-Generation Sequencing Companion Di..
AQ
05/04SPECTRUM PHARMACEUTICALS : MD Anderson, Spectrum Pharmaceuticals Complete Poziot..
AQ
More news
News from SeekingAlpha
05/21ONCOMED PHARMACEUTICALS : Assessing The Prospect Of A Potential Robust Winner 
05/18YOUR DAILY PHARMA SCOOP : RARE Shows Solid Data, Spectrum Up On Positive Results.. 
05/18ROUNDS REPORT : Eiger Moved Northbound While Spectrum Rallied Strongly Due To AD.. 
05/17HEALTHCARE - TOP 5 GAINERS / LOSERS : 20 am (05/17/2018) 
05/17Spectrum Pharma up 17% on late-stage Rolontis data 
Financials ($)
Sales 2018 109 M
EBIT 2018 -89,8 M
Net income 2018 -109 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 19,0x
Capi. / Sales 2019 18,3x
Capitalization 2 081 M
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 29,3 $
Spread / Average Target 45%
EPS Revisions
Managers
NameTitle
Joseph W. Turgeon President, Chief Executive Officer & Director
Stuart Mitchell Krassner Chairman
Thomas J. Riga Executive VP, Chief Operating & Commercial Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Guru Reddy Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.6.33%2 081
CELLTRION, INC.--.--%31 351
IQVIA HOLDINGS INC3.81%20 375
LONZA GROUP1.41%19 687
INCYTE CORPORATION-29.64%14 126
NEKTAR THERAPEUTICS42.83%13 568